Acute Lymphoblastic Leukaemia with an e1a3 BCR-ABL1 Fusion

By  

Acta Haematologica, Vol. 126, Iss. 4, 2011-09 ,pp. : 214-215

Karger

Access to resources Recommend Favorite

Role of Treatment in the Appearance and Selection of BCR-ABL1 Kinase Domain Mutations

By Razga Filip   Jurcek Tomas   Zackova Daniela   Dvorakova Dana   Toskova Martina   Jeziskova Ivana   Mayer Jiri   Racil Zdenek  

Molecular Diagnosis & Therapy, Vol. 16, Iss. 4, 2012-08 ,pp. : 251-259

Adis International

Access to resources Recommend Favorite

Drug resistance and BCR‐ABL kinase domain mutations in Philadelphia chromosome–positive acute lymphoblastic leukemia from the imatinib to the second‐generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement

By  

CANCER, Vol. 120, Iss. 7, 2014-04 ,pp. : 1002-1009

John Wiley & Sons Inc

Access to resources Recommend Favorite

BCR/ABL1 Kinase Domain Mutation Monitoring: Could Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Benefit As Well?

By  

Acta Haematologica, Vol. 134, Iss. 2, 2015-04 ,pp. : 69-70

Karger

Access to resources Recommend Favorite

BCR-ABL1⁺ Acute Myeloid Leukemia: Clonal Selection of a BCR-ABL1^- Subclone as a Cause of Refractory Disease with Nilotinib Treatment

By  

Acta Haematologica, Vol. 133, Iss. 2, 2014-11 ,pp. : 237-241

Karger

Access to resources Recommend Favorite